Introduction: Neonatal seizures are associated with worsened neurodevelopmental outcomes. Phenobarbital, the only US Food and Drug Administration (FDA)–approved treatment for neonatal seizures, can cause neuronal apoptosis and may worsen neurodevelopmental outcomes. Lacosamide may be an efficacious treatment for neonatal seizures. Methods: We assessed the impact of lacosamide boluses on seizure burden in a retrospective cohort of 15 neonates monitored with video electroencephalography (EEG). Medication bolus times and seizure start/end times on EEG tracings determined change in seizure burden. Results: Seven patients received lacosamide as first- or second-line treatment and 8 as third-line or later. Average 4-hour seizure burden decreased from 13% to 3% following lacosamide boluses (P = .002). Reduction in seizure burden greater than 30% followed 79% of boluses. Lacosamide was well tolerated; one patient experienced mild asymptomatic episodic bradycardia that medication taper resolved. Conclusions: Lacosamide significantly decreased seizure burden in this cohort. Prospective studies of lacosamide treatment for neonatal seizures are warranted.
PisaniFSpagnoliCFalsaperlaRNagarajanLRamantaniG. Seizures in the neonate: a review of etiologies and outcomes. Seizure. 2021;85:48–56. DOI: https://doi.org/10.1016/j.seizure.2020.12.023.
2.
GlassHCShellhaasRAWusthoffCJ, et al.Contemporary profile of seizures in neonates: a prospective cohort study. J Pediatr. 2016;174:98–103. e1. DOI: https://doi.org/10.1016/j.jpeds.2016.03.035.
3.
McBrideMCLaroiaNGuilletR. Electrographic seizures in neonates correlate with poor neurodevelopmental outcome. Neurology. 2000;55(4):506–513. DOI: https://doi.org/10.1212/wnl.55.4.506.
4.
SoulJSPresslerRAllenM, et al.Recommendations for the design of therapeutic trials for neonatal seizures. Pediatr Res. 2019;85(7):943–954. DOI: https://doi.org/10.1038/s41390-018-0242-2.
5.
KharoshankayaLStevensonNJLivingstoneV, et al.Seizure burden and neurodevelopmental outcome in neonates with hypoxic-ischemic encephalopathy. Dev Med Child Neurol. 2016;58(12):1242–1248. DOI: https://doi.org/10.1111/dmcn.13215.
6.
PayneETZhaoXYFrndovaH, et al.Seizure burden is independently associated with short term outcome in critically ill children. Brain. 2014;137(Pt 5):1429–1438. DOI: https://doi.org/10.1093/brain/awu042.
7.
PisaniFCerminaraCFuscoCSistiL. Neonatal status epilepticus vs recurrent neonatal seizures: clinical findings and outcome. Neurology. 2007;69(23):2177–2185. DOI: https://doi.org/10.1212/01.wnl.0000295674.34193.9e.
PainterMJScherMSSteinAD, et al.Phenobarbital compared with phenytoin for the treatment of neonatal seizures. N Engl J Med. 1999;341(7):485–489. DOI: https://doi.org/10.1056/nejm199908123410704.
10.
SharpeCReinerGEDavisSL, et al.Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics. 2020;145(6):e20193182. DOI: https://doi.org/10.1542/peds.2019-3182.
11.
SlaughterLAPatelADSlaughterJL. Pharmacological treatment of neonatal seizures: a systematic review. J Child Neurol. 2013;28(3):351–364. DOI: https://doi.org/10.1177/0883073812470734.
12.
BittigauPSifringerMGenzK, et al.Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc Natl Acad Sci U S A. 2002;99(23):15089–15094. DOI: https://doi.org/10.1073/pnas.222550499.
13.
ToroliraDSuchomelovaLWasterlainCGNiquetJ. Phenobarbital and midazolam increase neonatal seizure-associated neuronal injury. Ann Neurol. 2017;82(1):115–120. DOI: https://doi.org/10.1002/ana.24967.
14.
BittigauPSifringerMIkonomidouC. Antiepileptic drugs and apoptosis in the developing brain. Ann N Y Acad Sci. 2003;993:103–114. discussion 123-124. DOI: https://doi.org/10.1111/j.1749-6632.2003.tb07517.x.
15.
FarwellJRLeeYJHirtzDGSulzbacherSIEllenbergJHNelsonKB. Phenobarbital for febrile seizures—effects on intelligence and on seizure recurrence. N Engl J Med. 1990;322(6):364–369. DOI: https://doi.org/10.1056/nejm199002083220604.
16.
ErringtonACStöhrTHeersCLeesG. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol. 2008;73(1):157–169. DOI: https://doi.org/10.1124/mol.107.039867.
17.
HoltkampDOpitzTNiespodzianyIWolffCBeckH. Activity of the anticonvulsant lacosamide in experimental and human epilepsy via selective effects on slow Na(+) channel inactivation. Epilepsia. 2017;58(1):27–41. DOI: https://doi.org/10.1111/epi.13602.
18.
BamgboseOBoyleFKeanACStefanescuBMWingS. Tolerability and safety of lacosamide in neonatal population. J Child Neurol. 2023;38(3-4):137–141. DOI: https://doi.org/10.1177/08830738231164835.
NoguchiKKPalmerCWFuhlerNANeblockEFotedarMIkonomidouC. Lacosamide and Levetiracetam are not toxic to the developing mouse brain. Ann Neurol. Published online August 13, 2024. doi: 10.1002/ana.27052.
21.
UCB Cares. A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures (LENS). ID No. NCT04519645. 2021, March – present.
22.
AlmansaASLandersJAbendNS, et al.Retrospective, multicenter study of lacosamide to treat neonatal seizures. Platform presentation at: American Epilepsy Society Annual Meeting, December 4, 2023, Orlando, FL.
23.
MasseySLJensenFEAbendNS. Electroencephalographic monitoring for seizure identification and prognosis in term neonates. Semin Fetal Neonatal Med. 2018;23(3):168–174. DOI: https://doi.org/10.1016/j.siny.2018.01.001.
24.
Van RossumGDrakeFL. Python Reference Manual. Centrum voor Wiskunde en Informatica Amsterdam, 1995.
25.
VirtanenPGommersROliphantTE, et al.Scipy 1.0: Fundamental algorithms for scientific computing in Python. Nat Methods. 2020;17(3):261–272. DOI: https://doi.org/10.1038/s41592-019-0686-2.
26.
DelaunoisAColomarADepelchinBOCornetM. Cardiac safety of lacosamide: the non-clinical perspective. Acta Neurol Scand. 2015;132(5):337–345. DOI: https://doi.org/10.1111/ane.12413.
27.
RuddGDHaverkampWMasonJW, et al.Lacosamide cardiac safety: clinical trials in patients with partial-onset seizures. Acta Neurol Scand. 2015;132(5):355–363. DOI: https://doi.org/10.1111/ane.12414.
VerwoerdCLimjocoJRajamanickamVKnoxA. Efficacy of levetiracetam and phenobarbital as first-line treatment for neonatal seizures. J Child Neurol. 2022;37(5):401–409. DOI: https://doi.org/10.1177/08830738221086107.
30.
KilicdagHDaglıogluKErdoganS, et al.The effect of levetiracetam on neuronal apoptosis in neonatal rat model of hypoxic ischemic brain injury. Early Hum Dev. 2013;89(5):355–360. DOI: https://doi.org/10.1016/j.earlhumdev.2012.12.002.
31.
ModiSBAshaSIypeTLibuGRajanR. Cognitive adverse effects of lacosamide in patients with localization related epilepsy—a prospective observational study. medRxiv. 2021:2021.05.13.21257196. DOI: https://doi.org/10.1101/2021.05.13.21257196.
32.
IJffDVan VeenendaalTMajoieHde LouwAJansenJAldenkampA. Cognitive effects of lacosamide as adjunctive therapy in refractory epilepsy. Acta Neurol Scand. 2015;131(6):347–354. DOI: https://doi.org/10.1111/ane.12372.
